PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update

PTC Therapeutics, Inc.

Reconciliation of GAAP to Non-GAAP Projected Full Year 2019 R&D and SG&A Expense

(In thousands)

Low End of Range

High End of Range

Projected GAAP R&D and SG&A expense

$

395,000

$

405,000

Less: projected non-cash, stock-based compensation expense

35,000

35,000

Projected non-GAAP R&D and SG&A expense

$

360,000

$

370,000